Sanfilippo Syndrome (MPS III)

This is a rare genetic disorder affecting sugar breakdown. It causes sugars to build up in the body, leading to physical and mental health problems. There are different types (A, B, C, D) caused by different missing enzymes.

Condition

What people with Sanfilippo Syndrome (MPS III) report

Every report comes from a Lived member, sent anonymously.

NameHow it went

No reports yet

Add what worked for you with the search bar below

About Sanfilippo Syndrome (MPS III)

What It Is

Sanfilippo syndrome, also called mucopolysaccharidosis type III (MPS III), is a rare inherited disease that mainly damages the brain. Children usually seem healthy at birth and develop typically at first. Between about ages 1 and 4, development slows, often starting with delayed speech, and children later begin to lose skills they had already learned. Because it causes a gradual loss of memory, thinking and everyday abilities, it is often described as a form of childhood dementia. Behavior changes are a hallmark of the condition: hyperactivity, restlessness, chewing or mouthing objects, little sense of danger, tantrums and severe sleep problems are common. Body features tend to be milder than in other types of MPS, but can include coarse facial features, thick hair and eyebrows, a large head, frequent ear infections, hearing loss, loose stools and hernias. Over time, many people develop seizures, swallowing difficulty and loss of walking. There are four types, A, B, C and D. They look similar but differ in which enzyme is missing. Type A is the most common and often progresses fastest. The pace varies widely, even within a type: some children have a rapid course, while slower forms can allow survival into adulthood.

Causes & Risk Factors

MPS III is caused by changes (variants) in one of four genes. Each gene makes an enzyme that helps break down heparan sulfate, a large sugar molecule that cells normally recycle inside small compartments called lysosomes. When one of these enzymes is missing or does not work, heparan sulfate builds up in cells throughout the body. The brain is affected most, although researchers do not fully know why. The condition is inherited in an autosomal recessive pattern. A child is affected only when they inherit a nonworking copy of the same gene from both parents. Parents who each carry one copy are usually healthy and often have no family history, so a diagnosis is commonly the first sign that a family carries the gene. Nothing a parent did during pregnancy causes MPS III, and nothing in daily life triggers the disease or changes its underlying course.

How It's Diagnosed

Diagnosis is often delayed, sometimes by more than two years, because early signs such as speech delay, hyperactivity or autistic-like behavior are common in many children. Children are sometimes diagnosed with developmental delay, attention-deficit/hyperactivity disorder (ADHD) or autism before anyone tests for MPS III. A combination of speech or developmental delay with behavior changes, coarse facial features, frequent ear infections or bowel problems is a reason to ask about testing. MPS III is not part of routine newborn screening in the United States. Testing usually begins with a urine test for glycosaminoglycans (GAGs), the family of sugar molecules that includes heparan sulfate. A raised level suggests an MPS disorder, but urine tests can miss MPS III, so a normal result does not rule it out when suspicion is high. Confirmation comes from a blood or skin-cell test showing low activity of one of the four enzymes, which also identifies the type, and from genetic testing that finds the variants responsible. Genetic results matter for the whole family. They allow testing of brothers and sisters, carrier testing for relatives and testing in future pregnancies, and they can affect eligibility for clinical trials and new treatments. Because MPS III can be slow in some people, it is also considered in adults with any of three problems: early dementia, unexplained vision loss from retinal disease, or heart muscle disease.

Treatment Options

For type A, the US Food and Drug Administration (FDA) approved the first disease-specific treatment in September 2026. Fayuvi (rebisufligene etisparvovec) is a one-time gene therapy given through a vein. It uses a modified virus that cannot cause infection to deliver a working copy of the gene, so the body can make the missing enzyme. In the study behind the approval, children aged 2 to 5 maintained or improved their thinking skills, while comparable untreated children generally plateaued or declined. The study was small and had no randomized comparison group, so long-term results are still being followed. Treatment involves a course of steroid medicine, starting the day before the infusion and continuing for at least eight weeks afterward. The main serious risk is thrombotic microangiopathy, damage to small blood vessels, which is why the treatment center schedules follow-up monitoring. Because brain damage from MPS III appears largely irreversible, the therapy is aimed at children treated early. For types B, C and D, treatment is still supportive, and enzyme replacement and gene therapies are being studied in clinical trials. For every type, supportive care makes a real difference to comfort and daily life. A team that may include neurology, metabolic medicine, ear, nose and throat (ENT), eye, heart, dental, physical, occupational and speech therapy works together. Treating ear fluid with ear tubes and fitting hearing aids can noticeably improve communication. Picture boards and speech devices are best introduced before speech is lost. Sleep problems are managed with routines, safety measures at home and sometimes melatonin. Medicines for behavior may help some children but are tried carefully and for short periods, since evidence is limited. Seizures are treated with standard seizure medicines.

What to Expect

MPS III is progressive, and families usually move through changing stages. In the early years, behavior and sleep are often the hardest parts: many children are very active, have little sense of danger and wake often at night, which places heavy demands on parents. Structured routines, a safe home, school support and a one-to-one aide can help. Later, as speech, walking and swallowing decline, care shifts toward comfort, nutrition and preventing complications. Some people eventually need a feeding tube when eating by mouth is no longer safe. In the most severe forms, death usually comes before about age 20, often from pneumonia. Slower forms can allow survival well into adulthood. Children with MPS III often cannot say when they hurt, so pain from ears, teeth, hips, reflux or constipation may show up as new distress, agitation or worse sleep. Regular checkups, including hearing, vision, heart, dental and bone checks, help find these treatable problems. Sedation and anesthesia carry extra airway risk and should be planned in a hospital with experienced anesthesia staff. Caring for a child with a progressive disease is exhausting, and parents have high rates of stress and post-traumatic stress. Counseling, respite care, patient advocacy groups and an early connection with a palliative care team, which focuses on comfort and quality of life at any stage, support the whole family.

When to Seek Help

Ask about testing for MPS III if a young child's speech or development stalls or slips backward, especially alongside hyperactivity, severe sleep problems, coarse facial features or frequent ear infections. If a diagnosis of developmental delay, ADHD or autism does not fully explain a child's course, it is reasonable to ask whether metabolic testing has been done. For someone with MPS III, contact the care team promptly about a first seizure, a change in seizure pattern, coughing or a wet-sounding voice during meals, weight loss, or new and unexplained distress, agitation or worsening sleep, since these often signal pain or another treatable problem. Seek same-day medical care for fever with cough, fast or labored breathing, or other signs of a chest infection, because pneumonia can be hidden by usual behavior and progress quickly. Call 911 for a seizure lasting more than 5 minutes, seizures that repeat without recovery in between, or severe breathing trouble such as struggling to breathe or blue or gray lips. A child who has had Fayuvi needs the follow-up blood tests the treatment center schedules.

Questions to Ask Your Doctor

  1. 1.Which type of MPS III does my child have, and what does that suggest about how quickly it may progress?
  2. 2.Is my child eligible for gene therapy or a clinical trial, and what would treatment involve for our family?
  3. 3.Which specialists should be on our care team, and how often should hearing, vision, heart and bone checks happen?
  4. 4.How can we tell when behavior changes or poor sleep mean pain or another treatable problem?
  5. 5.What support is available for us, including respite care, school services, genetic counseling and palliative care?

Last reviewed • Oct 2026

Educational content, not medical advice.